Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics

Cell Cycle. 2012 Feb 1;11(3):428-9. doi: 10.4161/cc.11.3.19164. Epub 2012 Feb 1.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Animals
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / genetics
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Signal Transduction / drug effects
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / genetics
  • TOR Serine-Threonine Kinases / metabolism
  • Zebrafish / genetics*

Substances

  • Protein Kinase Inhibitors
  • TOR Serine-Threonine Kinases
  • Sirolimus